TNF-Inhibition with Etanercept for Graft-versus-Host Disease Prevention in High-Risk HCT: Lower TNFR1 Levels Correlate with Better Outcomes
Sung Won Choi(University of Michigan), John E. Levine(Icahn School of Medicine at Mount Sinai), James L.M. Ferrara(Tisch Hospital), David A. Hanauer(Associated Press), Kenneth R. Cooke(Johns Hopkins University), Sophie Paczesny(MUSC Hollings Cancer Center), Shin Mineishi(University of Alabama at Birmingham), Carrie L. Kitko(Vanderbilt University Medical Center), Tulio E. Rodriguez(Loyola University Medical Center), Pavan Reddy(Wichita State University), Gregory A. Yanik(University of Michigan), Thomas Braun(University of Michigan), Scott E. Smith(Loyola University Medical Center), Attaphol Pawarode(University of Michigan), Edward Peres(Henry Ford Hospital), Patrick J. Stiff(Loyola University Medical Center)
Cited by 62
Related Papers
Axicabtagene Ciloleucel CAR T-Cell Therapy in Refractory Large B-Cell Lymphoma
|New England Journal of Medicine|2017|6k
Tisagenlecleucel in Children and Young Adults with B-Cell Lymphoblastic Leukemia
|New England Journal of Medicine|2018|5.7k
National Institutes of Health Consensus Development Project on Criteria for Clinical Trials in Chronic Graft-versus-Host Disease: I. The 2014 Diagnosis and Staging Working Group Report
|Biology of Blood and Marrow Transplantation|2014|5.4k
Long-term safety and activity of axicabtagene ciloleucel in refractory large B-cell lymphoma (ZUMA-1): a single-arm, multicentre, phase 1–2 trial
|The Lancet Oncology|2018|2.3k
Voriconazole Compared with Liposomal Amphotericin B for Empirical Antifungal Therapy in Patients with Neutropenia and Persistent Fever
|New England Journal of Medicine|2002|986